Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts
Open accessThe DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
Acute myeloid leukemia (AML) is the most common type of acute leukemia, affecting older individuals at a median age of 67 years. Resistance to intensive induction chemotherapy is the major cause of death in elderly AML; hence, novel treatment strategies are warranted. CD33-directed antibody-drug conjugates (gemtuzumab ozogamicin) have been shown to improve overall survival, validating CD33 as a target for antibody-based therapy of AML. Here, we report the in vitro efficacy of BI 836858, a fully human, Fc-engineered, anti-CD33 antibody using AML cell lines and primary AML blasts as targets. BI 836858-opsonized AML cells significantly induced both autologous and allogeneic natural killer (NK)-cell degranulation and NK-cell-mediated antibody-dependent cellular cytotoxicity (ADCC). In vitro treatment of AML blasts with decitabine (DAC) or 5-azacytidine, 2 hypomethylating agents that show efficacy in older patients, did not compromise BI 836858-induced NK-cell-mediated ADCC. Evaluation of BI 836858-mediated ADCC in serial marrow AML aspirates in patients who received a 10-day course of DAC (pre-DAC, days 4, 11, and 28 post-DAC) revealed significantly higher ADCC in samples at day 28 post-DAC when compared with pre-DAC treatment. Analysis of ligands to activating receptors (NKG2D) showed significantly increased NKG2D ligand [NKG2DL] expression in day 28 post-DAC samples compared with pre-DAC samples; when NKG2DL receptor was blocked using antibodies, BI 836858-mediated ADCC was significantly decreased, suggesting that DAC enhances AML blast susceptibility to BI 836858 by upregulating NKG2DL. These data provide a rationale for combination therapy of Fc-engineered antibodies such as BI 836858 with azanucleosides in elderly patients with AML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“as well as CD33- and CD58-targeting mAbs”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Vasu et al., 2016
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
CD107a as a functional marker for the identification of natural killer cell activity
Alter, G., Malenfant, J. M., & Altfeld, M. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.08.008 · Cited by 1,410
Kantarjian, H. M., Thomas, X. G., Dmoszynska, A., Wierzbowska, A., Mazur, G., Mayer, J., Gau, J.-P., Chou, W.-C., Buckstein, R., Cermak, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9429 · Cited by 1,169
Multiple Comparisons: Theory and Methods
Christensen, R. (1997) · Technometrics · doi:10.1080/00401706.1997.10485097 · Cited by 1,098
Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961
Linear mixed models for longitudinal data
(2000) · Springer Series in Statistics · doi:10.1007/b98969 · Cited by 818
Hills, R. K., Castaigne, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S., Othus, M., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70281-5 · Cited by 721
Petersdorf, S. H., Kopecky, K. J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., Larson, R. A., Erba, H. P., Stiff, P. J., Stuart, R. K., et al. (2013) · Blood · doi:10.1182/blood-2013-01-466706 · Cited by 638
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
The Broad Spectrum of Human Natural Killer Cell Diversity
Freud, A. G., Mundy-Bosse, B. L., Yu, J., & Caligiuri, M. A. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.008 · Cited by 695
Advances in acute myeloid leukemia
Newell, L. F., & Cook, R. J. (2021) · BMJ · doi:10.1136/bmj.n2026 · Cited by 440
Immune escape and immunotherapy of acute myeloid leukemia
Vago, L., & Gojo, I. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129204 · Cited by 341
NK cell-based immunotherapy for cancer
Fang, F., Xiao, W., & Tian, Z. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.07.009 · Cited by 306
Metadata
- Authors
- Vasu, S., He, S., Cheney, C., Gopalakrishnan, B., Mani, R., Lozanski, G., Mo, X., Groh, V., Whitman, S. P., Konopitzky, R., Kössl, C., Bucci, D., Lucas, D. M., Yu, J., Caligiuri, M. A., Blum, W., Adam, P. J., Borges, E., Rueter, B., Heider, K.-H., Marcucci, G., & Muthusamy, N.
- Affiliations
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- The Ohio State University (US)
- University of Washington (US)
- Boehringer Ingelheim (Austria) (AT)
- Boehringer Ingelheim (Germany) (DE)
- City Of Hope National Medical Center (US)
- Corresponding author
- Vasu, Sumithira
- He, Shun
- Heider, Karl-Heinz
- Marcucci, Guido
- Muthusamy, Natarajan
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2016-06-09
- Volume
- 127
- Issue
- 23
- Pages
- 2879-2889
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC4900955
- OpenAlex
- W2417767096
- Cited by
- 93
- References
- 39
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 4 · 2023: 6 · 2022: 11 · 2021: 12 · 2020: 13 · 2019: 10 · 2018: 12 · 2017: 12 · 2016: 3
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Blood (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P01CA095426, R37CA068458, R01CA068458, R01CA135332, P30CA016058)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- acute myeloid leukemia, decitabine, anti-CD33 monoclonal antibody, antibody-dependent cellular cytotoxicity, natural killer cells, NKG2D ligands, NKG2D, azanucleosides, azacitidine, hypomethylating agents, combination therapy, elderly patients, Fc-engineered antibody, CD33
- MeSH terms
- Decitabine, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Cells, Cultured, Combined Modality Therapy, Cytotoxicity, Immunologic, Drug Synergism, Humans, Immunoglobulin Fc Fragments, Killer Cells, Natural, Recombinant Proteins, Leukemia, Myeloid, Acute, HL-60 Cells, Antibodies, Monoclonal, Humanized, Sialic Acid Binding Ig-like Lectin 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. https://app.cochat.ai/papers/10.1182/blood-2015-11-680546
- The paper
- Vasu, S., He, S., Cheney, C., Gopalakrishnan, B., Mani, R., Lozanski, G., Mo, X., Groh, V., Whitman, S. P., Konopitzky, R., Kössl, C., Bucci, D., Lucas, D. M., Yu, J., Caligiuri, M. A., Blum, W., Adam, P. J., Borges, E., Rueter, B., . . . Muthusamy, N. (2016). Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. Blood. https://doi.org/10.1182/blood-2015-11-680546
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.